High plasma levels of heparin-binding epidermal growth factor are associated with a more stable plaque phenotype and reduced incidence of coronary events

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 1, 2016, Pages 222-228

  Rattik, Sara ^a   Wigren, Maria ^a   Björkbacka, Harry ^a   Fredrikson, Gunilla Nordin ^a   Hedblad, Bo ^a   Siegbahn, Agneta ^b,c   Bengtsson, Eva ^a   Schiopu, Alexandru ^a   Edsfeldt, Andreas ^a,b   Dunér, Pontus ^a   Grufman, Helena ^a   Gonçalves, Isabel ^a,b   Nilsson, Jan ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Biomarkers; Cardiovascular event; Coronary disease; Myocytes; Smooth muscle

Indexed keywords

COLLAGEN; ELASTIN; EPIDERMAL GROWTH FACTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; BIOLOGICAL MARKER; HBEGF PROTEIN, HUMAN;

AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CAROTID ENDARTERECTOMY; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROTEIN BLOOD LEVEL; SMOOTH MUSCLE FIBER; BLOOD; CAROTID ARTERY DISEASES; CASE CONTROL STUDY; CORONARY DISEASE; INCIDENCE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTECTION; RISK ASSESSMENT; RISK FACTOR; RUPTURE; STATISTICAL MODEL; SWEDEN; UPREGULATION; VASCULAR SMOOTH MUSCLE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; CORONARY DISEASE; ENDARTERECTOMY, CAROTID; EPIDERMAL GROWTH FACTOR; FEMALE; HEPARIN-BINDING EGF-LIKE GROWTH FACTOR; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; PLATELET-DERIVED GROWTH FACTOR; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; RUPTURE, SPONTANEOUS; SWEDEN; UP-REGULATION;

EID: 84920272657     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304369     Document Type: Article

References (41)

1. Hansson GK. Infammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
2. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-325.
3. Biasillo G, Leo M, Della Bona R, Biasucci LM. Infammatory biomarkers and coronary heart disease: from bench to bedside and back. Intern Emerg Med. 2010;5:225-233.
4. Björkbacka H, Fredrikson GN, Nilsson J. Emerging biomarkers and intervention targets for immune-modulation of atherosclerosis-a review of the experimental evidence. Atherosclerosis. 2013;227:9-17.
5. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28:812-819.
6. Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med. 2007;17:253-258.
7. Raab G, Klagsbrun M. Heparin-binding EGF-like growth factor. Biochim Biophys Acta. 1997;1333:F179-F199.
8. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A hepa-rin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science. 1991;251:936-939.
9. Yoshizumi M, Kourembanas S, Temizer DH, Cambria RP, Quertermous T, Lee ME. Tumor necrosis factor increases transcription of the heparin-binding epidermal growth factor-like growth factor gene in vascular endo-thelial cells. J Biol Chem. 1992;267:9467-9469.
10. Temizer DH, Yoshizumi M, Perrella MA, Susanni EE, Quertermous T, Lee ME. Induction of heparin-binding epidermal growth factor-like growth factor mRNA by phorbol ester and angiotensin II in rat aortic smooth muscle cells. J Biol Chem. 1992;267:24892-24896.
11. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;16:585-601.
12. Elenius K, Paul S, Allison G, Sun J, Klagsbrun M. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J. 1997;16:1268-1278.
13. Higashiyama S, Lau K, Besner GE, Abraham JA, Klagsbrun M. Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J Biol Chem. 1992;267:6205-6212.
14. Nakata A, Miyagawa J, Yamashita S, Nishida M, Tamura R, Yamamori K, Nakamura T, Nozaki S, Kameda-Takemura K, Kawata S, Taniguchi N, Higashiyama S, Matsuzawa Y. Localization of heparin-binding epidermal growth factor-like growth factor in human coronary arteries. Possible roles of HB-EGF in the formation of coronary atherosclerosis. Circulation. 1996;94:2778-2786.
15. Miyagawa J, Higashiyama S, Kawata S, Inui Y, Tamura S, Yamamoto K, Nishida M, Nakamura T, Yamashita S, Matsuzawa Y. Localization of hepa-rin-binding EGF-like growth factor in the smooth muscle cells and macro-phages of human atherosclerotic plaques. J Clin Invest. 1995;95:404-411.
16. Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev. 2004;15:237-254.
17. Bonner JC. Regulation of PDGF and its receptors in fbrotic diseases. Cytokine Growth Factor Rev. 2004;15:255-273.
18. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991;253:1129-1132.
19. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest. 1992;89:507-511.
20. Kenagy RD, Hart CE, Stetler-Stevenson WG, Clowes AW. Primate smooth muscle cell migration from aortic explants is mediated by endogenous platelet-derived growth factor and basic fbroblast growth factor acting through matrix metalloproteinases 2 and 9. Circulation. 1997;96:3555-3560.
21. Higashiyama S, Abraham JA, Klagsbrun M. Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J Cell Biol. 1993;122:933-940.
22. Blotnick S, Peoples GE, Freeman MR, Eberlein TJ, Klagsbrun M. T lymphocytes synthesize and export heparin-binding epidermal growth factorlike growth factor and basic fbroblast growth factor, mitogens for vascular cells and fbroblasts: differential production and release by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA. 1994;91:2890-2894.
23. Besner G, Higashiyama S, Klagsbrun M. Isolation and characterization of a macrophage-derived heparin-binding growth factor. Cell Regul. 1990;1:811-819.
24. Arkonac BM, Foster LC, Sibinga NE, Patterson C, Lai K, Tsai JC, Lee ME, Perrella MA, Haber E. Vascular endothelial growth factor induces heparin-binding epidermal growth factor-like growth factor in vascular endothelial cells. J Biol Chem. 1998;273:4400-4405.
25. Igura T, Kawata S, Miyagawa J, Inui Y, Tamura S, Fukuda K, Isozaki K, Yamamori K, Taniguchi N, Higashiyama S, Matsuzawa Y. Expression of heparin-binding epidermal growth factor-like growth factor in neointimal cells induced by balloon injury in rat carotid arteries. Arterioscler Thromb Vasc Biol. 1996;16:1524-1531.
26. Matsumoto S, Kishida K, Shimomura I, Maeda N, Nagaretani H, Matsuda M, Nishizawa H, Kihara S, Funahashi T, Matsuzawa Y, Yamada A, Yamashita S, Tamura S, Kawata S. Increased plasma HB-EGF associated with obesity and coronary artery disease. Biochem Biophys Res Commun. 2002;292:781-786.
27. Kume N, Gimbrone MA Jr. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest. 1994;93:907-911.
28. Kozaki K, Kaminski WE, Tang J, Hollenbach S, Lindahl P, Sullivan C, Yu JC, Abe K, Martin PJ, Ross R, Betsholtz C, Giese NA, Raines EW. Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fbrous cap formation in ApoE null mice. Am J Pathol. 2002;161:1395-1407.
29. Edsfeldt A, Gonçalves I, Grufman H, Nitulescu M, Dunér P, Bengtsson E, Mollet IG, Persson A, Nilsson M, Orho-Melander M, Melander O, Björkbacka H, Nilsson J. Impaired fbrous repair: a possible contributor to atherosclerotic plaque vulnerability in patients with type II diabetes. Arterioscler Thromb Vasc Biol. 2014;34:2143-2150.
30. Pelisek J, Well G, Reeps C, Rudelius M, Kuehnl A, Culmes M, Poppert H, Zimmermann A, Berger H, Eckstein HH. Neovascularization and angiogenic factors in advanced human carotid artery stenosis. Circ J. 2012;76:1274-1282.
31. Murata K, Kotake C, Motoyama T. Collagen species in human aorta: with special reference to basement membrane-associated collagens in the intima and media and their alteration with atherosclerosis. Artery. 1987;14:229-247.
32. Shekhonin BV, Domogatsky SP, Muzykantov VR, Idelson GL, Rukosuev VS. Distribution of type I, III, IV and V collagen in normal and atherosclerotic human arterial wall: immunomorphological characteristics. Coll Relat Res. 1985;5:355-368.
33. Jacob T, Ascher E, Hingorani A, Khandros Y, Tsemekhin B, Zeien L, Gunduz Y. Differential proteolytic activity and induction of apoptosis in fbrous versus atheromatous plaques in carotid atherosclerotic disease. J Vasc Surg. 2001;33:614-620.
34. Clarke MC, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD, Bennett MR. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med. 2006;12:1075-1080.
35. Clarke MC, Littlewood TD, Figg N, Maguire JJ, Davenport AP, Goddard M, Bennett MR. Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcifcation and medial degeneration. Circ Res. 2008;102:1529-1538.
36. Cui Y, Sun YW, Lin HS, Su WM, Fang Y, Zhao Y, Wei XQ, Qin YH, Kohama K, Gao Y. Platelet-derived growth factor-BB induces matrix metalloproteinase-2 expression and rat vascular smooth muscle cell migration via ROCK and ERK/p38 MAPK pathways. Mol Cell Biochem. 2014;393:255-263.
37. Sluijter JP, Pulskens WP, Schoneveld AH, Velema E, Strijder CF, Moll F, de Vries JP, Verheijen J, Hanemaaijer R, de Kleijn DP, Pasterkamp G. Matrix metalloproteinase 2 is associated with stable and matrix metal-loproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke. 2006;37:235-239.
38. Rao VH, Kansal V, Stoupa S, Agrawal DK. MMP-1 and MMP-9 regulate epidermal growth factor-dependent collagen loss in human carotid plaque smooth muscle cells. Physiol Rep. 2014;2:e00224.
39. Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specifc juxtamembrane site. J Biol Chem. 1997;272:31730-31737.
40. Zhao Q, Zhao X, Cai Z, Li F, Yuan C, Cai J. Correlation of coronary plaque phenotype and carotid atherosclerotic plaque composition. Am J Med Sci. 2011;342:480-485.
41. Hellings WE, Peeters W, Moll FL, Piers SR, van Setten J, Van der Spek PJ, de Vries JP, Seldenrijk KA, De Bruin PC, Vink A, Velema E, de Kleijn DP, Pasterkamp G. Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: a prognostic study. Circulation. 2010;121:1941-1950.